SNS01-T: Phase Ib/IIa ongoing

Senesco said a data review committee recommended continuation to the fourth cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial of IV SNS01-T given twice weekly for 6 weeks after reviewing safety data from the third cohort, which showed the 0.2 mg/kg dose was well tolerated. The fourth cohort will enroll 6 patients and evaluate 0.375 mg/kg SNS01-T. The trial is evaluating 0.0125, 0.05, 0.2 and 0.375 mg/kg SNS01-T in about 15 patients with relapsed or refractory MM, MCL or DLBCL. ...